Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Summary

This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Timeline

Start

2019-05-01

Primary completion

2023-07-28

Completion

2027-02-12

Drugs

Indications